annual report 2009 - misleading statement?

http://www.avexa.com.au/investor/reports/annual_report_2009

A direct quote from Chairman's Report
Page 5 of 48 - paragraph 2.

"The development of apricitabine (ATC), Avexa?s lead compound for the treatment of drug-resistant HIV infections, made significant progress over the past year.
In June of this year, ATC completed the dose determination component of the Phase III trial and Avexa?s Data and Safety
Monitoring Board recommended selection of the 800mg ATC dose over the 1,200mg dose for the remainder of the study. This is a good result for our Company as it increases the commercial potential of ATC, because the 800mg is easier to formulate
into fixed dose combinations."

FIXED DOSE COMBINATION SEEM POSSIBLE THEN!